TNFRSF4 and breast carcinoma: In both MMTV-PyMT and 4T1 mammary carcinoma models, combination anti-OX40 plus anti-PD-1/L1 was associated with improved tumor control, but the synergistic effect was demonstrated only when anti-OX40 was administered in sequence with anti-PD-1/L1.